98%
921
2 minutes
20
During the COVID-19 pandemic, the lung ultrasound (LU) turned out to be a pivotal tool to study the lung involvement in the adult population, but the same was not well evaluated in children. We detected the LU patterns through an integrated approach with clinical−laboratory features in children hospitalized for COVID-19 in relation to the temporal trend of the Italian epidemic. We conducted a retrospective study which took place at a pediatric tertiary hospital from 15 March 2020 to 15 March 2021. We compared the characteristics of the initial phase of the first COVID-19 year—in the spring and summer (15 March−30 September 2020)—and those of the second phase—in the autumn and winter (1 October 2020−15 March 2021). Twenty-eight patients were studied both in the first and in the second phase of the first COVID-19 year. The disease severity score (DSS) was significantly greater in the second phase (p = 0.015). In the second phase of the first COVID-19 year, we detected a more significant occurrence of the following LU features than in the first phase: the irregular pleural line (85.71% vs. 60.71%; p = 0.035), the B-lines (89.29% vs. 60%; p = 0.003) and the several but non-coalescent B-lines (89.29% vs. 60%; p = 0.003). The LU score correlated significantly with the DSS, with a moderate relationship (r = 0.51, p < 0.001). The combined clinical, laboratory and ultrasound approaches might be essential in the evaluation of pulmonary involvement in children affected by COVID-19 during different periods of the pandemic.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139579 | PMC |
http://dx.doi.org/10.3390/children9050761 | DOI Listing |
Blood
September 2025
University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic, Hradec Králové, Czech Republic.
Epcoritamab is a subcutaneous CD3xCD20 bispecific antibody approved as monotherapy for relapsed/refractory (R/R) follicular lymphoma (FL). We evaluated fixed-duration epcoritamab with rituximab plus lenalidomide (R2) in R/R FL in arm 2 of EPCORE® NHL-2 (phase 1b/2; NCT04663347). Patients received epcoritamab (2 step-up doses, then 48-mg full doses) for up to 2 years and R2 for up to 12 cycles (28 days/cycle).
View Article and Find Full Text PDFFront Oral Health
August 2025
Department of Periodontology, Faculty of Dental Medicine, University of Belgrade, Belgrade, Serbia.
This study explores post-viral immune modulation in periodontal health using COVID-19 convalescence as a model. We hypothesized that post-COVID-19 recovery induces epigenetic alterations, measurable through salivary methyl-transferase-like 3 (METTL3) expression and clinical-periodontal parameters. The present research comprises results from two studies: the clinical study, which included a total of 83 systemically healthy adults stratified into four groups according to periodontal status and COVID-19 history, and the laboratory study on human parotid gland samples ( = 10).
View Article and Find Full Text PDFArch Med Res
September 2025
Postgraduate Program in Computational Systems Modeling, Federal University of Tocantins, Palmas, Tocantins, Brazil.
Background: The COVID-19 pandemic prompted rapid adaptations in healthcare systems worldwide. Academic medical centers, pivotal in healthcare education and research, rapidly adopted innovations. Brazilian state-owned university hospitals experienced unprecedented pressure on their services and were compelled to adopt new approaches to education and care delivery.
View Article and Find Full Text PDFInt J Med Microbiol
September 2025
Center for Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University, Jilin University, Changchun, Jilin 130000, China; Research Institute of Virology and AIDS research, The First Hospital of Jilin University, Jilin University, Changchun, Jilin 130000, China. Electronic addres
The emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) as the causative agent of COVID-19 precipitated a global health crisis of unprecedented scale. SARS-CoV-2 has been shown to interfere specifically with S phase progression during early stages of infection. Nucleocapsid (N) is an important structural protein.
View Article and Find Full Text PDF